Selected Grants
2/3 CTSA K12 Program at Duke University
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2025 - 2030Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Ki
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2029Stimulating Access to Research in Residency (StARR) - NIAID
Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of Allergy and Infectious Diseases · 2018 - 2029TRIO NRSA Training Core-Post Doc Trainee
Inst. Training Prgm or CMEMentor · Awarded by University of North Carolina - Chapel Hill · 2024 - 2028U2C/TL1 NC KUH TRIO Professional Development Core
ResearchCore Co-Lead · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028Stimulating Access to Research in Residency (StARR) - NHLBI
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 2018 - 2028APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Centers
ResearchPrincipal Investigator · Awarded by Wake Forest University Health Sciences · 2018 - 2028Kids: Nocturnal Investigation into Glomerular Disease, Hypertension, and Transcriptomics (kNIGHT)
ResearchPrincipal Investigator · Awarded by Northwell Health Care · 2024 - 2028Duke Preparing Research Scholars in Biomedical Sciences- Post-Baccalaureate Research Education Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of General Medical Sciences · 2022 - 2027Medical Scientist Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of General Medical Sciences · 2022 - 2027Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities that May Independently Contribute t
Clinical TrialPrincipal Investigator · Awarded by Vertex Pharmaceuticals Inc. · 2025 - 2027The Paired Undergraduate Mentoring Program (PUMP) in Uronephrology
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2022 - 2027Emerald2 RLY5016-208p Vifor- A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 6 Years of Age with Hyperkalaemia
Clinical TrialPrincipal Investigator · Awarded by CSL Behring LLC · 2024 - 2027REGULATORS OF CALCINEURIN PATHWAYS AS DIAGNOSTIC AND THERAPEUTIC TARGETS FOR NEPHROTIC SYNDROME
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2026VX21-147-301
Clinical TrialPrincipal Investigator · Awarded by Vertex Pharmaceuticals Inc. · 2023 - 2026Molecular Genetics of Nephrotic Syndrome
ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation, Inc. · 2023 - 2026A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Clinical TrialPrincipal Investigator · Awarded by Retrophin, Inc. · 2020 - 2026Defining the Landscape of HLA Risk Alleles in Primary Nephrotic Syndrome and Post Kidney Transplant Recurrence
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2026Duke Center for Advancement of Child Health (CAtCH).
Inst. Training Prgm or CMEMentor · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2021 - 2026A PHASE 2, OPEN-LABEL, SINGLE-ARM, COHORT STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SPARSENTAN TREATMENT IN PEDIATRIC SUBJECTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES (EPPIK)
Clinical TrialPrincipal Investigator · Awarded by Travere Therapeutics, Inc · 2021 - 2026A PHASE III, INTERNATIONAL, MULTICENTER, RANDOMISED OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB VERSUS MMF IN PATIENTS WITH CHILDHOOD ONSET IDIOPATHIC NEPHROTIC SYNDROME"
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2023 - 2025A study to test BI 764198 in people with a type of kidney disease called focal segmental glomerulosclerosis.
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2022 - 2025Defining the role of chloride channel 5 in maintaining podocyte structure and functions
ResearchPrincipal Investigator · Awarded by NEPHCURE Kidney International · 2023 - 2025Duke Physician Scientist Development program
ResearchPrincipal Investigator · Awarded by Burroughs Wellcome Fund · 2018 - 2025Improving Acute Kidney Injury Outcomes among Neonatal Intensive Care Unit Su
Inst. Training Prgm or CMEMentor · Awarded by Cornell University · 2023 - 2025Nephrotic Syndrome Rare Disease Clinical Research Network III (NEPTUNE III) ("Study")
ResearchPrincipal Investigator · Awarded by Regents of the University of Michigan · 2019 - 2025OPSD Duke PRIME Program
ResearchPrincipal Investigator · Awarded by Burroughs Wellcome Fund · 2020 - 2025Fund to Retain Clinical Scientists at Duke
ResearchCo-Director · Awarded by Doris Duke Charitable Foundation · 2016 - 2024Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
ResearchPrincipal Investigator · Awarded by University of Minnesota · 2018 - 2024Duke CTSA (TL1) Year 5
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients with Chronic Kidney Disease
Clinical TrialPrincipal Investigator · Awarded by Reata Pharmaceuticals, Inc. · 2021 - 2024CUREGN 2.0 - Midwest Pediatric Nephrology Consortium
ResearchPrincipal Investigator · Awarded by Research Institute at Nationwide Children's Hospital · 2019 - 2024Duke CTSA (KL2)
ResearchCore Co-Lead · Awarded by National Institutes of Health · 2018 - 2024Duke Preparing Research Scholars in Biomedical Sciences (PRIME) Program
ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation, Inc. · 2021 - 2023Postdoctoral Training in Genomic Medicine Research
Inst. Training Prgm or CMECo-Mentor · Awarded by National Institutes of Health · 2017 - 2023Duke Training Grant in Nephrology
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1995 - 2023Integrative genomics of glomerular disease in the CureGN cohort
ResearchPrincipal Investigator · Awarded by Columbia University · 2020 - 2023GENETIC BASIS OF CORTICOSTEROID RESPONSE IN CHILDHOOD NEPHROTIC SYNDROME
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2023H3 Africa Kidney Disease Research Network
ResearchPrincipal Investigator · Awarded by University of Ghana · 2017 - 2022The Role of Interleukin-15 Receptor-alpha Variants in the Pathogenesis of FSGS
ResearchCo-Mentor · Awarded by National Institutes of Health · 2017 - 2022Transmission electron microscope (TEM)
EquipmentMajor User · Awarded by National Institutes of Health · 2019 - 2021Physician Scientist Development Program
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Weill Cornell Medicine · 2020 - 2021A PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME
Clinical TrialPrincipal Investigator · Awarded by Reata Pharmaceuticals, Inc. · 2018 - 2020Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
ResearchPrincipal Investigator · Awarded by University of Minnesota · 2019 - 2020H3 AFRICA KIDNEY DISEASE COHORT STUDY
ResearchPrincipal Investigator · Awarded by University of Kansas · 2017 - 2020Pharmacokinetics of Cefepime in Children Receiving Continuous Renal Replacement Therapy
FellowshipPrincipal Investigator · Awarded by Thrasher Research Fund · 2018 - 2020A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms with Switchover, Pilot Study to Evlaluate the Efficacy and Safety of Intravenous Abatracept in Treamtne Resistant Nephrotic Syndrom (Focal Sebmental Glomerulosclerosis/Minimal Cha
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2020Genetics of childhood nephrotic syndrome
ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation · 2017 - 2019Functional and Phenotypic Characterization of a New FSGS Gene
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2019Integrative Proteomics & Metabolomics for Pediatric Glomerula Disease Biomarkers
ResearchPrincipal Investigator · Awarded by Research Institute at Nationwide Children's Hospital · 2014 - 2019Duke CTSA (UL1)
ResearchAssociate Director · Awarded by National Institutes of Health · 2013 - 2018ACTH for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome in Children
Clinical TrialPrincipal Investigator · Awarded by Emory University · 2014 - 2018Gene Discovery in Autosomal Dominant Focal Segmental Glomerulosclerosis
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2018Serial Block Face Scanning Electron Microscope
EquipmentMinor User · Awarded by National Institutes of Health · 2016 - 2018H3Africa Kidney Disease Research Network
ResearchPrincipal Investigator · Awarded by University of Ghana · 2015 - 2017Training Program in Inflammatory and Immunological Diseases
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1980 - 2017Identification of New Non-invasive Diagnostic Tools for Vesicoureteric Reflux (VUR)
ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation · 2014 - 2015IDENTIFICATION OF VUR GENES BY COMBINED LINKAGE ANALYSIS AND EXOME SEQUENCING
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2015A New Locus for Hereditary FSGS on Chromosome 2p
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2009 - 2014External Relationships
- Travere Therapeutics
- Vertex Pharmaceuticals Inc.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.